Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1992 1
1993 1
1994 1
1995 2
1996 4
1997 2
1998 2
2000 2
2001 3
2002 7
2003 9
2004 15
2005 18
2006 13
2007 28
2008 32
2009 34
2010 32
2011 44
2012 50
2013 69
2014 53
2015 59
2016 64
2017 63
2018 72
2019 71
2020 79
2021 79
2022 69
2023 66
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

922 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean Scd1 anti fatty liver (94 results)?
TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Park HS, Song JW, Park JH, Lim BK, Moon OS, Son HY, Lee JH, Gao B, Won YS, Kwon HJ. Park HS, et al. Autophagy. 2021 Sep;17(9):2549-2564. doi: 10.1080/15548627.2020.1834711. Epub 2020 Nov 16. Autophagy. 2021. PMID: 33190588 Free PMC article.
Here, we investigated the role and mechanism of TXNIP/VDUP1 (thioredoxin interacting protein), a key mediator of cellular stress responses, in the pathogenesis of NASH. Hepatic TXNIP expression was upregulated in nonalcoholic fatty liver disease (NAFLD) patients and …
Here, we investigated the role and mechanism of TXNIP/VDUP1 (thioredoxin interacting protein), a key mediator of cellular stress responses, …
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, Hao H, Xiong J. Du D, et al. Acta Pharm Sin B. 2022 Feb;12(2):558-580. doi: 10.1016/j.apsb.2021.09.019. Epub 2021 Sep 25. Acta Pharm Sin B. 2022. PMID: 35256934 Free PMC article. Review.
Tumor initiation and progression is driven by reprogramming of metabolism, in particular during HCC development. Recently, metabolic associated fatty liver disease (MAFLD), a reappraisal of new nomenclature for non-alcoholic fatty liver disease (NAFLD) …
Tumor initiation and progression is driven by reprogramming of metabolism, in particular during HCC development. Recently, metabolic associa …
Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma.
Yang Y, Cai J, Yang X, Wang K, Sun K, Yang Z, Zhang L, Yang L, Gu C, Huang X, Wang Z, Zhu X. Yang Y, et al. Mol Ther. 2022 Jun 1;30(6):2342-2353. doi: 10.1016/j.ymthe.2022.02.021. Epub 2022 Feb 19. Mol Ther. 2022. PMID: 35192934 Free PMC article.
Type 2 diabetes mellitus (DM2) is associated closely with non-alcoholic fatty liver disease (NAFLD) by affecting lipid metabolism, which may lead to non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma (HCC). ...Moreover, targeting METTL3/14 …
Type 2 diabetes mellitus (DM2) is associated closely with non-alcoholic fatty liver disease (NAFLD) by affecting lipid metabol …
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE((-/-)) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis.
Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, Kyrou I, Mantzoros CS, Kyriakopoulos G, Chatzigeorgiou A, Kalotychou V, Randeva MS, Chatha K, Kontzoglou K, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E. Nasiri-Ansari N, et al. Int J Mol Sci. 2021 Jan 15;22(2):818. doi: 10.3390/ijms22020818. Int J Mol Sci. 2021. PMID: 33467546 Free PMC article.
At the end of treatment, histomorphometric analysis was performed in liver, mRNA levels of Fasn, Screbp-1, Scd-1, Ppar-gamma, Pck-1, Mcp-1, Tnf-alpha, Il-6, F4/80, Atf4, Elf2alpha, Chop, Grp78, Grp94, chibp1, Ire1alpha, Atf6, mTor, Lc3b, Beclin-1, P62, Bcl-2 and Bax were m …
At the end of treatment, histomorphometric analysis was performed in liver, mRNA levels of Fasn, Screbp-1, Scd-1, Ppar-gamma, Pck-1, …
New targets for NAFLD.
Parlati L, Régnier M, Guillou H, Postic C. Parlati L, et al. JHEP Rep. 2021 Aug 8;3(6):100346. doi: 10.1016/j.jhepr.2021.100346. eCollection 2021 Dec. JHEP Rep. 2021. PMID: 34667947 Free PMC article. Review.
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by steatosis, liver inflammation, hepatocellular injury and progressive fibrosis. ...
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease worldwide. It is characterised by …
Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis.
Tong J, Lan XT, Zhang Z, Liu Y, Sun DY, Wang XJ, Ou-Yang SX, Zhuang CL, Shen FM, Wang P, Li DJ. Tong J, et al. Acta Pharmacol Sin. 2023 May;44(5):1014-1028. doi: 10.1038/s41401-022-01010-5. Epub 2022 Nov 2. Acta Pharmacol Sin. 2023. PMID: 36323829
Ferroptosis is a new form of regulated cell death characterized by excessive iron accumulation and uncontrollable lipid peroxidation. The role of ferroptosis in metabolic dysfunction-associated fatty liver disease (MAFLD) is not fully elucidated. In this study we co …
Ferroptosis is a new form of regulated cell death characterized by excessive iron accumulation and uncontrollable lipid peroxidation. The ro …
p53 protects against alcoholic fatty liver disease via ALDH2 inhibition.
Yao P, Zhang Z, Liu H, Jiang P, Li W, Du W. Yao P, et al. EMBO J. 2023 Apr 17;42(8):e112304. doi: 10.15252/embj.2022112304. Epub 2023 Feb 24. EMBO J. 2023. PMID: 36825429 Free PMC article.
By contrast, overexpression of SCD1 in liver promotes ethanol-induced fatty liver development in wild-type mice, while it has a mild effect on p53(-/-) or ALDH2(-/-) mice. Overall, our findings reveal a previously unrecognized function of p53 in alcoho …
By contrast, overexpression of SCD1 in liver promotes ethanol-induced fatty liver development in wild-type mice, …
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Wang M, Ma LJ, Yang Y, Xiao Z, Wan JB. Wang M, et al. Crit Rev Food Sci Nutr. 2019;59(sup1):S116-S129. doi: 10.1080/10408398.2018.1544542. Epub 2018 Dec 22. Crit Rev Food Sci Nutr. 2019. PMID: 30580553 Review.
Excess alcohol exposure leads to alcoholic liver disease (ALD), a predominant cause of liver-related morbidity and mortality worldwide. ...ABBREVIATION AA arachidonic acid ACC acetyl-CoA carboxylase ACLY ATP-citrate lyase ACO acyl-CoA oxidase ALA alpha-linolenic aci …
Excess alcohol exposure leads to alcoholic liver disease (ALD), a predominant cause of liver-related morbidity and mortality w …
Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2alpha/PPARalpha pathway.
Chen J, Chen J, Fu H, Li Y, Wang L, Luo S, Lu H. Chen J, et al. Am J Physiol Endocrinol Metab. 2019 Oct 1;317(4):E710-E722. doi: 10.1152/ajpendo.00052.2019. Epub 2019 Aug 20. Am J Physiol Endocrinol Metab. 2019. PMID: 31430204 Free article.
This study aimed to investigate whether hypoxia can affect nonalcoholic fatty liver disease (NAFLD) progression and the associated mechanisms, specifically regarding the hypoxia-inducible factor (HIF)-2alpha/peroxisome proliferator-activated receptor (PPAR)alpha pat …
This study aimed to investigate whether hypoxia can affect nonalcoholic fatty liver disease (NAFLD) progression and the associ …
FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption.
Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, Jarrett KE, Chan AP, Brearley-Sholto MC, Wahlström A, Ashby JW, Barshop W, Wohlschlegel J, Calkin AC, Liu Y, Thorell A, Meikle PJ, Drew BG, Mack JJ, Marschall HU, Tarling EJ, Edwards PA, de Aguiar Vallim TQ. Clifford BL, et al. Cell Metab. 2021 Aug 3;33(8):1671-1684.e4. doi: 10.1016/j.cmet.2021.06.012. Epub 2021 Jul 15. Cell Metab. 2021. PMID: 34270928 Free PMC article.
FXR agonists are used to treat non-alcoholic fatty liver disease (NAFLD), in part because they reduce hepatic lipids. ...Decreases in MUFA are due to FXR-dependent repression of Scd1, Dgat2, and Lpin1 expression, which is independent of SHP and SREBP1c. ...
FXR agonists are used to treat non-alcoholic fatty liver disease (NAFLD), in part because they reduce hepatic lipids. ...Decre …
922 results